DE602005016849D1 - Substituierte Morpholin and Thiomorpholin Derivate - Google Patents

Substituierte Morpholin and Thiomorpholin Derivate

Info

Publication number
DE602005016849D1
DE602005016849D1 DE602005016849T DE602005016849T DE602005016849D1 DE 602005016849 D1 DE602005016849 D1 DE 602005016849D1 DE 602005016849 T DE602005016849 T DE 602005016849T DE 602005016849 T DE602005016849 T DE 602005016849T DE 602005016849 D1 DE602005016849 D1 DE 602005016849D1
Authority
DE
Germany
Prior art keywords
substituted morpholine
thiomorpholine derivatives
thiomorpholine
derivatives
morpholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016849T
Other languages
English (en)
Inventor
Thornoee Christian Wenzel
Mario Rottlaender
Nikolay Khanzhin
Andreas Ritzen
William Patrick Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005016849(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE602005016849D1 publication Critical patent/DE602005016849D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE602005016849T 2004-03-12 2005-03-09 Substituierte Morpholin and Thiomorpholin Derivate Active DE602005016849D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12

Publications (1)

Publication Number Publication Date
DE602005016849D1 true DE602005016849D1 (de) 2009-11-05

Family

ID=37730781

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005007474T Active DE602005007474D1 (en) 2004-03-12 2005-03-09 Substituierte morpholin- und thiomorpholinderivate
DE602005016849T Active DE602005016849D1 (de) 2004-03-12 2005-03-09 Substituierte Morpholin and Thiomorpholin Derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602005007474T Active DE602005007474D1 (en) 2004-03-12 2005-03-09 Substituierte morpholin- und thiomorpholinderivate

Country Status (32)

Country Link
US (6) US7501414B2 (de)
EP (3) EP1727809B8 (de)
JP (1) JP5006184B2 (de)
KR (2) KR101411204B1 (de)
CN (2) CN1930138A (de)
AR (1) AR049784A1 (de)
AT (2) ATE443702T1 (de)
AU (1) AU2005221762B2 (de)
BR (1) BRPI0508570B8 (de)
CA (1) CA2559397C (de)
CO (1) CO5721001A2 (de)
CY (2) CY1110392T1 (de)
DE (2) DE602005007474D1 (de)
DK (2) DK1727809T3 (de)
EA (1) EA015120B1 (de)
EG (1) EG25344A (de)
ES (2) ES2306087T3 (de)
HK (1) HK1172618A1 (de)
HR (1) HRP20090685T1 (de)
IL (1) IL177859A (de)
MY (2) MY147786A (de)
NO (1) NO337161B1 (de)
NZ (1) NZ549133A (de)
PL (2) PL1727809T3 (de)
PT (2) PT1947093E (de)
RS (2) RS51066B (de)
SG (1) SG151254A1 (de)
SI (2) SI1727809T1 (de)
TW (2) TWI349666B (de)
UA (2) UA102517C2 (de)
WO (1) WO2005087754A1 (de)
ZA (2) ZA200607286B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1861394A1 (de) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituierte pyridinderivate
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
EP2554162A1 (de) * 2006-02-07 2013-02-06 H. Lundbeck A/S Verwendung von KCNQ-Oeffnern zur Behandlung oder Abschwächung der Symptomen von Schizophrenie
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
EP2061465B1 (de) 2006-08-23 2013-04-10 Valeant Pharmaceuticals International 4-(n-azacycloalkyl) anilidderivate als kaliumkanalmodulatoren
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
AU2008281112A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of KCNQ potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2011026891A1 (en) * 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
AU2011275393B2 (en) 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
EP2844247A4 (de) * 2012-04-20 2015-11-25 Anderson Gaweco Ror-modulatoren und deren verwendungen
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20170360726A1 (en) * 2014-12-05 2017-12-21 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
EP3366683A1 (de) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Zyklische amide, acetamide und harnstoffe als kalium kanal öffner
EP3917907A1 (de) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulatoren von kaliumionenkanälen und verwendungen davon
IL282188A (en) * 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
EP0946528B1 (de) * 1996-12-23 2003-04-09 Bristol-Myers Squibb Pharma Company SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
IL130286A0 (en) * 1996-12-23 2000-06-01 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor Xa inhibitors
EP1042299A1 (de) 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Stickstoffenthaltende heteroaromaten mit ortho-substituierten p1 gruppen als faktor-xa-inhibitoren
AU3110999A (en) 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
CA2410489A1 (en) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
KR20030070916A (ko) * 2001-01-16 2003-09-02 아스트라제네카 아베 치료용 크로몬 화합물
KR20030070917A (ko) * 2001-01-16 2003-09-02 아스트라제네카 아베 치료용 크로만 화합물
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives

Also Published As

Publication number Publication date
JP2007528880A (ja) 2007-10-18
BRPI0508570B8 (pt) 2021-05-25
CN102516204A (zh) 2012-06-27
TWI357901B (en) 2012-02-11
EP1727809A1 (de) 2006-12-06
SI1727809T1 (sl) 2008-10-31
US8299075B2 (en) 2012-10-30
ES2306087T3 (es) 2008-11-01
PT1947093E (pt) 2009-12-22
US20090143369A1 (en) 2009-06-04
EP1947093A1 (de) 2008-07-23
US20060167248A1 (en) 2006-07-27
AU2005221762B2 (en) 2011-06-09
TW200811121A (en) 2008-03-01
TW200533359A (en) 2005-10-16
JP5006184B2 (ja) 2012-08-22
ATE443702T1 (de) 2009-10-15
CY1110392T1 (el) 2015-04-29
US20100063033A1 (en) 2010-03-11
KR20120136422A (ko) 2012-12-18
US20090137571A1 (en) 2009-05-28
UA102517C2 (ru) 2013-07-25
RS50606B (sr) 2010-05-07
DK1947093T3 (da) 2010-02-01
ZA200709718B (en) 2008-09-25
ZA200607286B (en) 2008-04-30
TWI349666B (en) 2011-10-01
EP2138487A1 (de) 2009-12-30
CA2559397C (en) 2010-08-10
RS51066B (sr) 2010-10-31
IL177859A0 (en) 2006-12-31
US8012962B2 (en) 2011-09-06
NZ549133A (en) 2010-09-30
NO20064599L (no) 2006-12-08
NO337161B1 (no) 2016-02-01
PT1727809E (pt) 2008-08-13
CA2559397A1 (en) 2005-09-22
SG151254A1 (en) 2009-04-30
WO2005087754A1 (en) 2005-09-22
BRPI0508570B1 (pt) 2018-11-21
EP1727809B1 (de) 2008-06-11
EP1727809B8 (de) 2008-10-29
EA015120B1 (ru) 2011-06-30
CY1109656T1 (el) 2014-08-13
AR049784A1 (es) 2006-09-06
DE602005007474D1 (en) 2008-07-24
US20110294787A1 (en) 2011-12-01
BRPI0508570A (pt) 2007-08-14
US20100063036A1 (en) 2010-03-11
PL1947093T3 (pl) 2010-02-26
UA90670C2 (en) 2010-05-25
EP1947093B1 (de) 2009-09-23
DK1727809T3 (da) 2008-09-29
CN102516204B (zh) 2016-01-20
US7632835B2 (en) 2009-12-15
AU2005221762A1 (en) 2005-09-22
MY147786A (en) 2013-01-31
KR101411204B1 (ko) 2014-06-23
US7501414B2 (en) 2009-03-10
CN1930138A (zh) 2007-03-14
ES2334076T3 (es) 2010-03-04
EG25344A (en) 2011-12-14
MY143698A (en) 2011-06-30
KR20060128004A (ko) 2006-12-13
SI1947093T1 (sl) 2010-01-29
IL177859A (en) 2013-02-28
HRP20090685T1 (hr) 2010-02-28
CO5721001A2 (es) 2007-01-31
PL1727809T3 (pl) 2008-11-28
US7812023B2 (en) 2010-10-12
ATE398112T1 (de) 2008-07-15
EA200601686A1 (ru) 2007-02-27
HK1172618A1 (zh) 2013-04-26
EP1947093B9 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
ATE443702T1 (de) Substituierte morpholin and thiomorpholin derivate
CY2015036I1 (el) Νεα παραγωγα οξαζολιδινονης
IS8152A (is) Tálmar fosfatídýlínósítól 3-kínasa
NL1030486A1 (nl) Dibenzylamineverbindingen en derivaten.
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
DK1725553T3 (da) Tetrahydropyridoindolderivater
ATE540935T1 (de) Chinazolinderivate
IS8180A (is) Nýjar besímídasólafleiður
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DK1682493T3 (da) Amidoacetonitrilderivater
ATE352550T1 (de) Chinazolinderivate
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
IS8045A (is) Púrín-6-ón-afleiður
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate
NO20054552D0 (no) Peleanker med utvendige skovler
DK1706373T3 (da) Amidoacetonitrilderivater
DE502005008147D1 (de) Funktion
DE10349030B4 (de) Axialverstellvorrichtung
ES1055831Y (es) Sabana bajera ajustable.
ITBS20040107A1 (it) Supporto registrabile
ITTE20040004A1 (it) Sughermix - intonaco premiscelato
ITBS20040098A1 (it) Sgabello

Legal Events

Date Code Title Description
8364 No opposition during term of opposition